Multivariate Cox proportional hazards analysis of overall survival for patients with CLL younger than 70 years at diagnosis
| Variable . | HR* (95% CI) . | P . |
|---|---|---|
| Low CLLU1 and mutated IgVH | 1.00 (reference) | — |
| High CLLU1 and mutated IgVH | 8.00 (2.00-32.04) | .003 |
| Low CLLU1 and unmutated IgVH | 23.69 (4.44-126.36) | <.001 |
| High CLLU1 and unmutated IgVH | 7.08 (1.93-25.94) | .003 |
| ZAP-70 positive versus ZAP-70 negative | 2.65 (0.85-8.31) | .094 |
| CD38+ versus CD38− | 0.38 (0.11-1.25) | .11 |
| del(17p)/del(11q) versus trisomy 12/normal/del(13q) | 3.44 (0.97-12.13) | .055 |
| Variable . | HR* (95% CI) . | P . |
|---|---|---|
| Low CLLU1 and mutated IgVH | 1.00 (reference) | — |
| High CLLU1 and mutated IgVH | 8.00 (2.00-32.04) | .003 |
| Low CLLU1 and unmutated IgVH | 23.69 (4.44-126.36) | <.001 |
| High CLLU1 and unmutated IgVH | 7.08 (1.93-25.94) | .003 |
| ZAP-70 positive versus ZAP-70 negative | 2.65 (0.85-8.31) | .094 |
| CD38+ versus CD38− | 0.38 (0.11-1.25) | .11 |
| del(17p)/del(11q) versus trisomy 12/normal/del(13q) | 3.44 (0.97-12.13) | .055 |
— indicates not applicable.
Based on a model including ZAP-70, CD38, cytogenetics, and interaction between CLLU1 expression and mutational status.